Pfizer (PFE) free cash flow

Free cash flow · fiscal 2025
$9.08B

Pfizer (PFE) generated free cash flow of $9.08B in fiscal 2025 (the year ended December 31, 2025). That is 7.7% lower than the $9.84B of fiscal 2024. Figures as of 18 Nov 2026, 11:38 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2025
$9.08B
Change on fiscal 2024
−7.7%
Growth, 5 years
−5.7% a year
Growth, 10 years
−3.7% a year
Highest on record
$29.87Bfiscal 2021
Lowest on record
$4.79Bfiscal 2023
Fiscal years on record
192007–2025

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Pfizer free cash flow, in more detail

Over the five fiscal years to 2025 free cash flow shrank at a compound 5.7% a year; over ten years the rate was −3.7% a year. Across the 19 fiscal years on record (2007–2025), the highest was $29.87B in fiscal 2021 and the lowest $4.79B in fiscal 2023.

History · 19 fiscal years

Free cash flow by fiscal year

Pfizer free cash flow, year by year

Pfizer (PFE) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2025$9.08B 7.7% down
2024$9.84B 105.2% up
2023$4.79B 81.6% down
2022$26.03B 12.8% down
2021$29.87B 145.3% up
2020$12.18B 15.5% up
2019$10.54B 23.8% down
2018$13.84B 6.8% down
2017$14.85B 3.3% up
2016$14.37B 8.1% up
2015$13.29B 16.3% down
2014$15.89B 3.6% down
2013$16.48B 6.9% up
2012$15.42B 17.0% down
2011$18.58B 86.9% up
2010$9.94B 35.4% down
2009$15.38B 7.0% down
2008$16.54B 44.1% up
2007$11.47B—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Pfizer and comparable companies
CompanyFree cash flowFiscal year
Abbott Laboratories ABT$7.40B2025
Novo Nordisk NVODKK 28.99B2025
Pfizer PFE$9.08B2025
Danaher DHR$5.26B2025
Intuitive Surgical ISRG$2.49B2025
Vertex Pharmaceuticals VRTX$3.19B2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on PFE

Pfizer, figure by figure

Pfizer (PFE) overview: price, valuation and scorecardAll health care companies by market value

Pfizer free cash flow: questions and answers

What is Pfizer's free cash flow?

Pfizer (PFE) generated free cash flow of $9.08B in fiscal 2025 (the year ended December 31, 2025). That is 7.7% lower than the $9.84B of fiscal 2024.

What is the growth rate of Pfizer's free cash flow?

Over the five fiscal years to 2025 free cash flow shrank at a compound 5.7% a year; over ten years the rate was −3.7% a year.

What are the highest and lowest free cash flow figures on record for Pfizer?

Across the 19 fiscal years on record (2007–2025), the highest was $29.87B in fiscal 2021 and the lowest $4.79B in fiscal 2023.

How is Pfizer's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Pfizer it is on record here for 19 fiscal years, 2007 to 2025.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Pfizer (PFE) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/PFE/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.